Biblio

Author Title [ Type

] Year

Filters: Author is Stary, Jan [Clear All Filters]

Journal Article

Mark C, Meshinchi S, Joyce B, Gibson B, Harrison C, Bergmann AK, Goemans BF, Pronk CJan H, Lapillonne H, Leverger G, et al. Treatment outcomes of childhood PICALM::MLLT10 acute leukaemias. Br J Haematol. 2023.

Erlacher M, Andresen F, Sukova M, Stary J, de Moerloose B, Bosch Jvan der We, Dworzak M, Seidel MG, Polychronopoulou S, Beier R, et al. Spontaneous remission and loss of monosomy 7: a window of opportunity for young children with SAMD9L syndrome. Haematologica. 2023.

Sahoo SS, Pastor VB, Goodings C, Voss RK, Kozyra EJ, Szvetnik A, Noellke P, Dworzak M, Stary J, Locatelli F, et al. Publisher Correction: Clinical evolution, genetic landscape and trajectories of clonal hematopoiesis in SAMD9/SAMD9L syndromes. Nat Med. 2021.

Wlodarski MW, Hirabayashi S, Pastor V, Stary J, Hasle H, Masetti R, Dworzak M, Schmugge M, van den Heuvel-Eibrink M, Ussowicz M, et al. Prevalence, clinical characteristics and prognosis of GATA2-related myelodysplastic syndromes (MDS) in children and adolescents. Blood. 2015.

Doz F, Locatelli F, Baruchel A, Blin N, de Moerloose B, Frappaz D, Dworzak M, Fischer M, Stary J, Fuertig R, et al. Phase I dose-escalation study of volasertib in pediatric patients with acute leukemia or advanced solid tumors. Pediatr Blood Cancer. 2019:e27900.

Attarbaschi A, Möricke A, Harrison CJ, Mann G, Baruchel A, de Moerloose B, Conter V, Devidas M, Elitzur S, Escherich G, et al. Outcomes of Childhood Noninfant Acute Lymphoblastic Leukemia With 11q23/ Rearrangements in a Modern Therapy Era: A Retrospective International Study. J Clin Oncol. 2022:JCO2201297.

Raetz EA, Rebora P, Conter V, Schrappe M, Devidas M, Escherich G, Imai C, de Moerloose B, Schmiegelow K, Burns MA, et al. Outcome for Children and Young Adults With T-Cell ALL and Induction Failure in Contemporary Trials. J Clin Oncol. 2023:JCO2300088.

van Weelderen RElise, Harrison CJ, Klein K, Jiang Y, Abrahamsson J, Alonzo T, Aplenc R, Arad-Cohen N, Bart-Delabesse E, Buldini B, et al. Optimized Cytogenetic Risk-Group Stratification of KMT2A-Rearranged Pediatric Acute Myeloid Leukemia. Blood Adv. 2024.

van Weelderen RE, Klein K, Harrison CJ, Jiang Y, Abrahamsson J, Arad-Cohen N, Bart-Delabesse E, Buldini B, de Moerloose B, Dworzak MN, et al. Measurable Residual Disease and Fusion Partner Independently Predict Survival and Relapse Risk in Childhood -Rearranged Acute Myeloid Leukemia: A Study by the International Berlin-Frankfurt-Münster Study Group. J Clin Oncol. 2023:JCO2202120.

Conter V, Valsecchi MGrazia, Cario G, Zimmermann M, Attarbaschi A, Stary J, Niggli F, Pozza LDalla, Elitzur S, Silvestri D, et al. Four Additional Doses of PEG-L-Asparaginase During the Consolidation Phase in the AIEOP-BFM ALL 2009 Protocol Do Not Improve Outcome and Increase Toxicity in High-Risk ALL: Results of a Randomized Study. J Clin Oncol. 2023:JCO2301388.

Yoshimi A, van den Heuvel-Eibrink MM, Baumann I, Schwarz S, Simonitsch-Klupp I, de Paepe P, Campr V, Kerndrup GBirk, Sullivan MO', Devito R, et al. Comparison of horse and rabbit anti-thymocyte globulin in immunosuppressive therapy for refractory cytopenia of childhood. Haematologica. 2013.

Campbell M, Kiss C, Zimmermann M, Riccheri C, Kowalczyk J, Felice MS, Kuzmanovic M, Kovács G, Kosmidis H, Gonzalez A, et al. Childhood Acute Lymphoblastic Leukemia: Results of the Randomized Acute Lymphoblastic Leukemia Intercontinental-Berlin-Frankfurt-Münster 2009 Trial. J Clin Oncol. 2023:JCO2201760.